Review

A Review of Cutaneous Manifestations of Systemic Lupus Erythematosus in Clinical Practice

Austin Callahan * and Allison Baxter

Posted Date: 5 August 2025

doi: 10.20944/preprints202508.0218.v1

Keywords: erythematosus; dermatology

 doi:10.20944/preprints202508.0218.v1

Review

A Review of Cutaneous Manifestations of Systemic Lupus Erythematosus in Clinical Practice

Austin Callahan [1,*] and Allison Baxter [2]

[1] Independent Researcher, USA

[2] Independent Researcher, USA

* Correspondence: topcited@hotmail.com

Abstract

Systemic Lupus Erythematosus (SLE) is a complex, multisystem autoimmune disorder characterized by a diverse array of clinical manifestations, with cutaneous symptoms being among the most common and impactful. This review aims to collate existing literature on the cutaneous manifestations of SLE, emphasizing their clinical relevance, diagnostic challenges, and implications for management in clinical practice. The cutaneous manifestations of SLE are varied, encompassing a spectrum of lesions that can significantly affect a patient's quality of life. Key cutaneous features include the classic butterfly rash, discoid lesions, photosensitivity, and mucosal ulcers, each associated with distinct pathophysiological mechanisms. The review categorizes these manifestations into acute, subacute, and chronic forms, providing a detailed analysis of their clinical characteristics, histopathological findings, and associated systemic features. Furthermore, the review examines the role of environmental factors, genetic predispositions, and immunological pathways in the development of skin lesions in SLE patients. It highlights the importance of recognizing these manifestations early, as they can serve as initial indicators of systemic involvement and disease flares. The interplay between cutaneous symptoms and systemic disease activity is explored, illustrating how skin findings can inform broader clinical assessments and treatment strategies. In addition to clinical presentation, this review discusses the diagnostic modalities used to evaluate cutaneous manifestations, including dermoscopy and skin biopsy, which aid in differentiating SLE from other dermatological conditions. Management strategies, ranging from topical therapies to systemic immunosuppressive agents, are reviewed, underscoring the need for a tailored approach that considers individual patient factors and disease severity. By synthesizing current knowledge on the cutaneous aspects of SLE, this review provides clinicians with enhanced insights into the dermatological dimensions of the disease. It advocates for a multidisciplinary approach to care, integrating dermatologists, rheumatologists, and primary care providers in the management of SLE. The findings underscore the importance of ongoing research to further elucidate the underlying mechanisms of cutaneous manifestations and to develop innovative therapeutic strategies. In conclusion, a thorough understanding of the cutaneous manifestations of systemic lupus erythematosus is essential for effective clinical practice. Recognizing these manifestations not only aids in the early diagnosis of SLE but also enhances the overall management of this complex disease, ultimately improving patient outcomes and quality of life. This review serves as a comprehensive resource for clinicians seeking to deepen their understanding of the dermatological features of SLE and their implications for patient care.

Keywords: erythematosus; dermatology

 doi:10.20944/preprints202508.0218.v1

Chapter 1: Introduction to Cutaneous Manifestations of Systemic Lupus Erythematosus

1.1. Background

Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by the production of autoantibodies and a wide array of clinical manifestations. Although SLE can affect virtually any organ system, its cutaneous manifestations are often the most visible and can significantly impact patients' quality of life. Understanding these dermatological features is essential for timely diagnosis, comprehensive management, and improved patient outcomes.

The epidemiology of SLE reveals a higher prevalence in women, particularly during their reproductive years, suggesting a potential hormonal influence on disease pathogenesis. The estimated prevalence of SLE varies globally, with rates ranging from 20 to 150 cases per 100,000 individuals, depending on geographic and ethnic factors. Despite significant advancements in understanding SLE, its etiology remains incompletely elucidated, involving a complex interplay of genetic, environmental, and immunological factors.

1.2. Rationale for the Review

Given the multifaceted nature of SLE and the prominent role of cutaneous manifestations, there is a pressing need to systematically review and synthesize the existing literature on this subject. This chapter aims to provide a comprehensive overview of the cutaneous manifestations associated with SLE, contextualizing their clinical significance and implications for patient management. By focusing on these dermatological features, healthcare providers can enhance their diagnostic acumen and develop targeted therapeutic strategies.

1.3. Objectives of the Review

The primary objectives of this review are as follows:

1. **To categorize and describe the various cutaneous manifestations of SLE**, detailing their clinical features, histopathology, and associated systemic involvement.

2. **To explore the underlying pathophysiological mechanisms** contributing to skin lesions in SLE, including genetic predispositions and environmental triggers.

3. **To examine the diagnostic approaches** utilized in clinical practice, including the role of dermoscopy and skin biopsy in differentiating SLE from other dermatological conditions.

4. **To evaluate current management strategies**, highlighting the importance of individualized treatment plans that account for the severity of cutaneous manifestations and overall disease activity.

 doi:10.20944/preprints202508.0218.v1

5. **To underscore the importance of a multidisciplinary approach** in managing SLE, integrating dermatologists, rheumatologists, and primary care providers to optimize patient care.

1.4. Structure of the Review

This review is structured to provide a coherent exploration of the cutaneous manifestations of SLE. Following this introductory chapter, Chapter 2 will delve into the classification of cutaneous manifestations, categorizing them into acute, subacute, and chronic forms, and discussing their clinical relevance. Chapter 3 will focus on the pathophysiological mechanisms involved in the development of these skin lesions, integrating insights from recent research in immunology and genetics.

Chapter 4 will address the diagnostic modalities employed in identifying cutaneous manifestations, emphasizing the roles of clinical examination, dermoscopy, and histopathological evaluation. In Chapter 5, we will review management strategies for cutaneous manifestations, including both topical and systemic therapies, and discuss the importance of a patient-centered approach to care.

Finally, Chapter 6 will summarize the key findings of this review, highlighting areas for future research and the clinical implications of understanding cutaneous manifestations in SLE. By synthesizing current knowledge, this review aims to serve as a valuable resource for clinicians seeking to enhance their understanding and management of this complex disease.

1.5. Conclusion

In conclusion, the cutaneous manifestations of systemic lupus erythematosus represent a critical aspect of the disease that warrants thorough investigation and understanding. As the visibility of these lesions often correlates with the patient's psychosocial well-being, effective recognition and management are paramount. This review aims to provide a comprehensive framework for healthcare providers to navigate the challenges associated with cutaneous manifestations of SLE, ultimately leading to improved patient care and outcomes.

Chapter 2: Cutaneous Manifestations of Systemic Lupus Erythematosus

2.1. Introduction

Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disorder that primarily affects women of childbearing age but can occur in individuals across all demographics. Among the myriad of symptoms associated with SLE, cutaneous manifestations are particularly prevalent, affecting approximately 70-80% of patients at some point during the disease course. These dermatological signs are not only crucial for diagnosis but also serve as indicators of systemic involvement and disease activity. This chapter delves into the diverse array of cutaneous manifestations of SLE, categorizing them based on their clinical features, pathophysiology, and implications for management in clinical practice.

2.2. Classification of Cutaneous Manifestations

Cutaneous manifestations of SLE can be broadly classified into three categories: acute, subacute, and chronic.

 doi:10.20944/preprints202508.0218.v1

2.2.1. Acute Cutaneous Manifestations

Acute cutaneous manifestations are typically transient and can occur during disease flares. The most recognized acute manifestation is the "butterfly rash" or malar rash, characterized by a fixed erythematous rash across the cheeks and bridge of the nose. This rash is often exacerbated by sunlight exposure and is considered pathognomonic for SLE.

Clinical Characteristics:

- **Malar Rash:** Presents as a symmetrical, erythematous rash that spares the nasolabial folds.
- **Photosensitivity:** A heightened sensitivity to ultraviolet (UV) light that triggers skin lesions, often exacerbating existing rashes.

The acute manifestations serve as vital diagnostic markers, as their presence may prompt further investigation for systemic involvement.

2.2.2. Subacute Cutaneous Manifestations

Subacute cutaneous lupus erythematosus (SCLE) is characterized by annular or papulosquamous lesions that typically arise on sun-exposed areas. Unlike acute manifestations, SCLE can persist for weeks to months and may remit with adequate treatment.

Clinical Characteristics:

- **Annular Lesions:** Ring-shaped, erythematous patches that may exhibit scaling.
- **Psoriasiform Lesions:** Resembling psoriasis, these lesions can be itchy and often occur on the trunk and upper extremities.

SCLE is distinguished by its association with specific autoantibodies (e.g., anti-Ro/SSA antibodies), which can aid in diagnostic clarity.

2.2.3. Chronic Cutaneous Manifestations

Chronic cutaneous manifestations, particularly discoid lupus erythematosus (DLE), are characterized by well-defined, scarring lesions that can lead to significant morbidity. DLE lesions are often localized to the face, scalp, and ears.

Clinical Characteristics:

- **Discoid Lesions:** Raised, erythematous plaques with keratotic scaling and central scarring.
- **Mucosal Ulcers:** Painful lesions that can occur in the oral cavity and may complicate the patient's quality of life.

Chronic manifestations require more intensive management due to their potential for scarring and disfigurement.

 doi:10.20944/preprints202508.0218.v1

2.3. Pathophysiology of Cutaneous Manifestations

The pathogenesis of cutaneous manifestations in SLE is multifactorial, involving genetic, environmental, and immunological factors. Genetic predispositions, such as specific human leukocyte antigen (HLA) alleles, can increase susceptibility to SLE and its cutaneous manifestations. Environmental triggers, particularly UV radiation, can exacerbate skin lesions through complex immunological pathways.

Immunological Mechanisms:

- **Autoantibody Formation:** The production of autoantibodies, particularly against nuclear antigens, leads to immune complex deposition in the skin, triggering inflammatory responses.
- **Cytokine Release:** Dysregulated cytokine profiles contribute to the inflammatory milieu, promoting the development of lesions.
- **T-cell Activation:** Aberrant activation of T-helper cells can further drive the autoimmune response, influencing skin pathology.

Understanding these underlying mechanisms is crucial for developing targeted therapeutic interventions.

2.4. Diagnostic Approaches

Accurate diagnosis of cutaneous manifestations in SLE is essential for effective management. Clinical evaluation remains the cornerstone of diagnosis, supported by laboratory tests and, when necessary, histopathological examination.

2.4.1. Clinical Evaluation

A thorough clinical history and physical examination are paramount. Clinicians should assess the morphology, distribution, and duration of skin lesions, alongside systemic symptoms. The presence of specific cutaneous features can provide significant diagnostic clues.

2.4.2. Laboratory Investigations

Laboratory investigations, including antinuclear antibody (ANA) testing and specific autoantibody panels (e.g., anti-dsDNA, anti-Smith), can support the diagnosis of SLE. The presence of anti-Ro/SSA antibodies is particularly associated with SCLE.

2.4.3. Histopathological Examination

Skin biopsies may be performed to differentiate SLE from other dermatological conditions, such as psoriasis or dermatitis. Histopathological findings often reveal interface dermatitis, liquefactive degeneration of the basement membrane, and the presence of perivascular lymphocytic infiltrates.

 doi:10.20944/preprints202508.0218.v1

2.5. Management of Cutaneous Manifestations

Management strategies for cutaneous manifestations of SLE must be individualized, considering the severity of the lesions and the overall disease activity.

2.5.1. Topical Therapies

For localized lesions, topical corticosteroids and calcineurin inhibitors can effectively reduce inflammation and improve symptoms. Antimalarial agents, particularly hydroxychloroquine, are often employed as a first-line systemic treatment for cutaneous manifestations due to their efficacy and favorable safety profile.

2.5.2. Systemic Therapies

In cases of extensive or refractory skin involvement, systemic immunosuppressive therapies, such as corticosteroids, azathioprine, or mycophenolate mofetil, may be indicated. Newer biologic agents targeting specific pathways (e.g., B-cell depletion therapies) are being explored and may offer additional options for treatment.

2.5.3. Photoprotection

Given the role of UV exposure in exacerbating skin lesions, rigorous photoprotection measures, including the use of broad-spectrum sunscreens and protective clothing, are essential components of management.

2.6. Quality of Life Considerations

The impact of cutaneous manifestations on patients' quality of life cannot be overstated. Dermatological involvement can lead to significant psychosocial distress, affecting self-esteem and social interactions. Incorporating dermatological assessment into routine SLE management is crucial to address these concerns effectively.

2.7. Conclusion

Cutaneous manifestations of systemic lupus erythematosus represent a critical aspect of the disease, with significant implications for diagnosis, management, and patient quality of life. A comprehensive understanding of the diverse skin manifestations, their underlying pathophysiology, and appropriate management strategies is essential for clinicians. By recognizing and addressing the dermatological dimensions of SLE, healthcare providers can improve patient outcomes and enhance overall care in this complex autoimmune disorder. Ongoing research into the mechanisms and treatment of cutaneous manifestations will continue to inform and refine clinical practice, fostering better management of SLE and its associated challenges.

Chapter 3: Cutaneous Manifestations of Systemic Lupus Erythematosus

3.1. Introduction

Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disorder characterized by a wide range of clinical manifestations, among which cutaneous symptoms are particularly prevalent and significant. The skin manifestations of SLE not only serve as some of the most visible signs of the disease but also play a crucial role in its diagnosis, monitoring, and management. This chapter provides an in-depth analysis of the various cutaneous manifestations associated with SLE, examining their clinical features, pathophysiology, diagnostic approaches, and management strategies.

 doi:10.20944/preprints202508.0218.v1

3.2. Overview of Cutaneous Manifestations

Cutaneous manifestations of SLE can be categorized into three primary types: acute, subacute, and chronic lesions. Each category presents distinct clinical features and implications for patient management.

3.2.1. Acute Cutaneous Manifestations

Acute cutaneous manifestations are often transient and typically occur during disease flares. The most recognized acute manifestation is the classic "butterfly rash" (malar rash), characterized by erythematous plaques across the cheeks and nose. This rash is often exacerbated by sunlight exposure and may be associated with systemic symptoms such as fever and malaise.

Another acute manifestation is the urticarial rash, which may resemble hives and can occur spontaneously. This rash is often itchy and can vary in appearance, presenting as raised wheals or erythematous patches. Acute lesions may also include vesicular or bullous eruptions, which, although less common, can signify severe disease activity.

3.2.2. Subacute Cutaneous Manifestations

Subacute cutaneous lupus erythematosus (SCLE) is characterized by erythematous, annular, or psoriasiform plaques that are often associated with significant photosensitivity. These lesions typically appear on sun-exposed areas, including the arms, shoulders, and chest. SCLE lesions may resolve with appropriate treatment but often recur, particularly with sun exposure or during periods of systemic activity.

Histopathologically, SCLE lesions reveal a band-like infiltrate of lymphocytes at the dermal-epidermal junction, as well as keratinocyte damage, which differentiates them from other forms of cutaneous lupus. The identification of anti-Ro/SSA antibodies is frequently associated with SCLE, providing additional diagnostic insight.

3.2.3. Chronic Cutaneous Manifestations

Chronic cutaneous manifestations, primarily discoid lupus erythematosus (DLE), present as well-defined, erythematous plaques with adherent keratotic scaling. These plaques may be localized to the face, scalp, or ears and can lead to scarring and permanent pigmentary changes. DLE can occur independently of systemic disease but is often seen in conjunction with SLE.

Histologically, DLE lesions demonstrate similar findings to those of SCLE, including epidermal atrophy and a perivascular infiltrate in the dermis. The potential for significant scarring necessitates early recognition and management.

3.3. Pathophysiology of Cutaneous Manifestations

Understanding the underlying pathophysiological mechanisms of cutaneous manifestations in SLE is essential for developing targeted therapeutic strategies. The immune dysregulation that characterizes SLE leads to increased production of autoantibodies and inflammatory cytokines, contributing to the development of skin lesions.

3.3.1. Immune Mechanisms

The presence of autoantibodies, particularly antinuclear antibodies (ANA) and anti-double-stranded DNA antibodies, is central to SLE pathogenesis. These antibodies can form immune complexes that deposit in the skin, triggering a local inflammatory response. Cytokines such as interferon-alpha and tumor necrosis factor-alpha (TNF-α) play pivotal roles in perpetuating inflammation and promoting keratinocyte activation, leading to the characteristic skin lesions.

 doi:10.20944/preprints202508.0218.v1

3.3.2. Environmental Triggers

Environmental factors, including ultraviolet (UV) light exposure, infections, and hormonal changes, can exacerbate cutaneous manifestations of SLE. UV radiation, in particular, induces keratinocyte apoptosis and enhances the immune response, leading to the development of lesions in predisposed individuals.

3.4. Diagnostic Approaches

3.4.1. Clinical Evaluation

A thorough clinical evaluation is fundamental in diagnosing cutaneous manifestations of SLE. The clinician must carefully assess the morphology, distribution, and associated symptoms of skin lesions. A comprehensive medical history, including the onset of skin symptoms and any systemic manifestations, is also crucial.

3.4.2. Laboratory Investigations

Laboratory investigations complement the clinical assessment. Routine serological tests, including ANA and anti-dsDNA antibody testing, are essential for confirming SLE diagnosis. The presence of specific autoantibodies, such as anti-Ro/SSA and anti-La/SSB, can aid in correlating skin manifestations with systemic disease activity.

3.4.3. Histopathology

Skin biopsy remains a definitive diagnostic tool for evaluating cutaneous manifestations. Histopathological examination can reveal characteristic findings, such as interface dermatitis and follicular plugging, which help differentiate SLE from other dermatological conditions.

3.5. Management of Cutaneous Manifestations

Effective management of cutaneous manifestations of SLE requires a multidisciplinary approach, incorporating dermatologic and rheumatologic expertise. Treatment strategies are tailored to the individual patient, taking into account the severity of skin lesions, systemic involvement, and patient preferences.

3.5.1. Topical Therapies

For localized lesions, topical corticosteroids are often the first-line treatment. High-potency corticosteroids can effectively reduce inflammation and promote healing of acute and chronic lesions. Topical calcineurin inhibitors may also be utilized for sensitive areas or when corticosteroid use is contraindicated.

3.5.2. Systemic Therapies

In cases of extensive or refractory cutaneous involvement, systemic therapies may be warranted. Antimalarials, such as hydroxychloroquine, are commonly used as first-line agents for managing cutaneous symptoms and preventing disease flares. In more severe cases, systemic corticosteroids or immunosuppressive agents may be required to control active disease.

3.5.3. Photoprotection

Given the significant role of UV exposure in exacerbating cutaneous manifestations, photoprotection is a crucial component of management. Patients should be educated on the importance of using broad-spectrum sunscreen, wearing protective clothing, and avoiding peak sun exposure.

 doi:10.20944/preprints202508.0218.v1

3.6. Conclusion

Cutaneous manifestations of Systemic Lupus Erythematosus are diverse and can significantly impact patient quality of life. A comprehensive understanding of these manifestations, along with their pathophysiology and management strategies, is essential for clinicians involved in the care of SLE patients. Early recognition and appropriate treatment of cutaneous symptoms can help mitigate their effects, enhance patient well-being, and improve overall disease management. As research continues to evolve, ongoing efforts to elucidate the complex interplay of immune mechanisms and environmental factors will be critical in developing innovative therapies and improving patient outcomes in SLE.

Chapter 4: Cutaneous Manifestations of Systemic Lupus Erythematosus

4.1. Introduction

Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disorder that manifests through a wide array of clinical symptoms, particularly affecting the skin. Cutaneous manifestations are not only prevalent among SLE patients but also serve as critical indicators of disease activity and prognosis. This chapter delves into the various cutaneous manifestations associated with SLE, exploring their clinical features, underlying pathophysiology, diagnostic approaches, and management strategies. A comprehensive understanding of these manifestations is essential for clinicians, as early recognition and appropriate intervention can significantly improve patient outcomes.

4.2. Overview of Cutaneous Manifestations

The cutaneous manifestations of SLE are diverse and can be classified into three primary categories: acute, subacute, and chronic. Each category encompasses distinct clinical features, which can vary in presentation, severity, and systemic association.

4.2.1. Acute Cutaneous Manifestations

Acute cutaneous manifestations are often the first signs of SLE and include:

- **Butterfly Rash (Malar Rash):** This characteristic rash appears as a erythematous, butterfly-shaped lesion across the cheeks and nose. It is often exacerbated by sunlight exposure and is associated with systemic disease activity.

- **Acute Drug-Induced Lupus Erythematosus:** Certain medications can induce symptoms resembling SLE, including cutaneous manifestations similar to the butterfly rash. Differentiating between drug-induced lupus and idiopathic SLE is crucial for management.

4.2.2. Subacute Cutaneous Manifestations

Subacute cutaneous lupus erythematosus (SCLE) is characterized by:

 doi:10.20944/preprints202508.0218.v1

- **Annular and Papulosquamous Lesions:** These lesions typically present as erythematous papules with scaling, often located on sun-exposed areas. They may resolve spontaneously but can recur with sun exposure.

- **Photosensitivity:** Many SLE patients experience exacerbation of cutaneous lesions upon exposure to ultraviolet (UV) light, highlighting the need for sun protection in management.

4.2.3. Chronic Cutaneous Manifestations

Chronic cutaneous lupus erythematosus primarily includes:

- **Discoid Lupus Erythematosus (DLE):** DLE lesions are typically well-defined, erythematous plaques with a central atrophic scar, often leading to scarring and hair loss if located on the scalp. Chronicity poses a risk of skin malignancy in long-standing lesions.

- **Mucosal Ulcers:** Oral and nasal mucosal lesions can occur, presenting as painful ulcers that may complicate the clinical picture of SLE.

4.3. Pathophysiology

The pathogenesis of cutaneous manifestations in SLE is multifactorial, involving genetic predisposition, environmental triggers, and immunological dysregulation.

4.3.1. Genetic Factors

Genetic susceptibility plays a pivotal role in SLE, with various loci associated with increased risk. Polymorphisms in genes related to immune regulation and apoptosis, such as the complement component genes and the Fc receptor genes, have been implicated in the development of cutaneous lesions.

4.3.2. Environmental Triggers

Ultraviolet light exposure is a well-established trigger for cutaneous manifestations in SLE. It can induce apoptosis in keratinocytes, leading to the release of nuclear antigens, triggering an autoimmune response. Other environmental factors, such as infections and certain medications, can also precipitate or exacerbate skin lesions.

4.3.3. Immunological Dysregulation

The hallmark of SLE is the presence of autoantibodies, including anti-nuclear antibodies (ANA) and anti-double-stranded DNA antibodies. The interaction between these autoantibodies and skin cells can lead to immune complex deposition, inflammation, and subsequent cutaneous lesions.

 doi:10.20944/preprints202508.0218.v1

Dysregulation of T and B cell responses contributes to the chronic inflammatory state observed in SLE patients.

4.4. Diagnosis

The diagnosis of cutaneous manifestations of SLE relies on a combination of clinical evaluation, laboratory tests, and sometimes histopathological examination.

4.4.1. Clinical Evaluation

A thorough patient history and physical examination are essential for identifying cutaneous manifestations. Clinicians should assess the morphology, distribution, and duration of lesions, as well as associated systemic symptoms.

4.4.2. Laboratory Tests

Laboratory tests, including serological assays for autoantibodies (e.g., ANA, anti-dsDNA), play a crucial role in supporting the diagnosis of SLE. Elevated complement levels may indicate active disease, while specific antibody profiles can provide insights into disease subtype.

4.4.3. Histopathological Examination

In ambiguous cases, a skin biopsy may be warranted. Histopathological findings characteristic of SLE include interface dermatitis, perivascular inflammation, and the presence of apoptotic keratinocytes. This information can aid in differentiating SLE from other dermatologic conditions.

4.5. Management Strategies

The management of cutaneous manifestations in SLE requires a multidisciplinary approach, incorporating dermatological and rheumatological expertise.

4.5.1. General Measures

Sun protection is paramount for all SLE patients, as UV exposure can exacerbate skin lesions. Broad-spectrum sunscreens, protective clothing, and UV-blocking accessories are essential components of patient education.

4.5.2. Topical Therapies

For localized skin lesions, topical corticosteroids and calcineurin inhibitors are commonly used. These agents can reduce inflammation and alleviate symptoms associated with cutaneous manifestations.

4.5.3. Systemic Therapies

In cases of severe or widespread cutaneous involvement, systemic immunosuppressive therapies may be necessary. Agents such as hydroxychloroquine, corticosteroids, and other immunosuppressants (e.g., azathioprine, mycophenolate mofetil) can effectively manage cutaneous and systemic manifestations of SLE.

4.5.4. Emerging Therapies

Recent advancements in targeted therapies, such as biologic agents (e.g., belimumab) and Janus kinase (JAK) inhibitors, show promise for patients with refractory cutaneous manifestations. Ongoing clinical trials are crucial to evaluate their efficacy and safety in SLE.

 doi:10.20944/preprints202508.0218.v1

4.6. Conclusion

Cutaneous manifestations of systemic lupus erythematosus represent a significant aspect of the disease, impacting both clinical management and patient quality of life. A thorough understanding of these manifestations, their pathophysiology, and management strategies is essential for clinicians involved in the care of SLE patients. By recognizing and addressing cutaneous symptoms early, healthcare providers can not only enhance disease management but also improve overall patient outcomes, emphasizing the importance of a holistic approach in treating this complex autoimmune disorder. Continued research is necessary to further elucidate the underlying mechanisms driving cutaneous manifestations and to develop innovative therapies that can optimize patient care.

Chapter 5: Clinical Implications and Management of Cutaneous Manifestations of Systemic Lupus Erythematosus

5.1. Introduction

Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disorder characterized by a wide range of clinical manifestations affecting various organ systems. Among these, cutaneous manifestations are particularly significant due to their prevalence, visibility, and potential impact on patients' quality of life. This chapter aims to provide a comprehensive overview of the clinical implications of cutaneous manifestations in SLE, focusing on their diagnostic significance, management strategies, and the holistic approach to patient care.

5.2. Clinical Significance of Cutaneous Manifestations

5.2.1. Prevalence and Presentation

Cutaneous manifestations are present in approximately 70-80% of SLE patients at some point during the disease course. The most common skin lesions include the classic malar rash, discoid lupus erythematosus, photosensitive rashes, and mucosal ulcers. These manifestations can vary in appearance and severity, necessitating a nuanced understanding for accurate diagnosis and management.

Malar Rash

The malar rash, often described as a butterfly-shaped erythematous rash across the cheeks and nose, is one of the hallmark features of SLE. It typically exacerbates with sun exposure and can be indicative of systemic activity. Clinicians should be aware that while the presence of a malar rash is suggestive of SLE, it is not exclusive to the disease and may occur in other conditions, such as rosacea or dermatomyositis.

Discoid Lupus Erythematosus

Discoid lesions are often chronic and can lead to scarring and pigmentary changes. These lesions are characterized by erythematous plaques with adherent keratotic scaling and can occur on sun-exposed areas. Their presence often indicates a risk for systemic disease, making recognition and management essential.

5.2.2. Diagnostic Challenges

The diagnosis of SLE is multifactorial and requires a thorough clinical evaluation, including a detailed history and physical examination. The variability of cutaneous manifestations can pose diagnostic challenges, particularly in differentiating SLE from other autoimmune and dermatological conditions.

 doi:10.20944/preprints202508.0218.v1

Differential Diagnosis

Key considerations in the differential diagnosis include conditions such as dermatomyositis, psoriasis, and seborrheic dermatitis. Utilizing diagnostic tools such as dermoscopy and skin biopsy can aid in establishing a definitive diagnosis, allowing for timely and appropriate management.

5.2.3. Impact on Quality of Life

The psychosocial implications of cutaneous manifestations in SLE patients are profound. Skin lesions can lead to self-esteem issues, social withdrawal, and depression. Clinicians must recognize these aspects and incorporate mental health support into the treatment plan, ensuring a holistic approach to patient care.

5.3. Management Strategies

5.3.1. General Principles of Management

Management of cutaneous manifestations of SLE involves a combination of pharmacological and non-pharmacological strategies. The goal is to control symptoms, prevent exacerbations, and minimize the impact of skin lesions on quality of life.

5.3.2. Topical Therapies

Topical corticosteroids remain the first-line treatment for localized skin lesions, such as discoid lupus. They are effective in reducing inflammation and promoting healing. However, prolonged use can lead to skin atrophy, necessitating careful monitoring and judicious use.

Calcineurin Inhibitors

For patients who cannot tolerate corticosteroids or require long-term management, calcineurin inhibitors such as tacrolimus and pimecrolimus are valuable alternatives. They have shown efficacy in treating both facial and discoid lesions without the side effects associated with long-term steroid use.

5.3.3. Systemic Therapies

In cases of widespread or resistant cutaneous disease, systemic therapies may be warranted. Antimalarials, particularly hydroxychloroquine, are commonly used for their efficacy in managing skin manifestations and systemic disease activity. Regular ophthalmological monitoring is essential due to the risk of retinal toxicity.

Immunosuppressants

In more severe cases, immunosuppressants such as azathioprine or mycophenolate mofetil can be considered. These agents help in controlling systemic inflammation but require careful monitoring for potential adverse effects, including increased infection risk.

5.3.4. Photoprotection

Given the photosensitivity associated with SLE, sun protection is crucial. This includes the use of broad-spectrum sunscreens, protective clothing, and avoidance of direct sunlight during peak hours. Educating patients on effective sun protection strategies can significantly reduce the incidence of skin flares.

5.3.5. Psychosocial Interventions

Addressing the psychosocial aspects of living with SLE is vital. Support groups, counseling, and patient education can help patients cope with the emotional burden of visible skin lesions.

 doi:10.20944/preprints202508.0218.v1

Encouraging open communication about body image and self-esteem can foster a supportive therapeutic relationship.

5.4. Multidisciplinary Approach to Care

The management of cutaneous manifestations in SLE requires a multidisciplinary approach, involving rheumatologists, dermatologists, and mental health professionals. Collaborative care models enhance patient outcomes by ensuring comprehensive management of both systemic and dermatological aspects of the disease.

5.4.1. Role of Dermatologists

Dermatologists play a critical role in the diagnosis and management of skin manifestations, providing expertise in dermatological procedures such as biopsies and advanced therapies. Their involvement can lead to more tailored and effective treatment plans.

5.4.2. Role of Rheumatologists

Rheumatologists are essential for managing the systemic components of SLE, ensuring that treatment regimens are adjusted based on disease activity. They can provide guidance on systemic therapies that may influence cutaneous manifestations.

5.4.3. Integrative Care Models

An integrative care model that includes nutritionists, psychologists, and physical therapists can further enhance management by addressing the multifactorial nature of SLE. Such a model fosters a comprehensive approach that benefits the whole patient, not just the disease.

5.5. Conclusion

The cutaneous manifestations of systemic lupus erythematosus are clinically significant and can profoundly impact patients' lives. Recognizing and understanding these manifestations is crucial for timely diagnosis and effective management. A multidisciplinary approach that incorporates both medical and psychosocial support is essential for optimizing patient outcomes. As research continues to evolve, ongoing education and awareness among healthcare providers will be key in improving the management of cutaneous manifestations in SLE, ultimately enhancing the quality of life for affected individuals.

Chapter 6: Comprehensive Analysis of Cutaneous Manifestations of Systemic Lupus Erythematosus in Clinical Practice

Introduction

Systemic Lupus Erythematosus (SLE) is a multifaceted autoimmune disorder characterized by dysregulation of the immune system, leading to widespread inflammation and tissue damage. Among the myriad of clinical manifestations, cutaneous symptoms are particularly prevalent and can significantly impact a patient's quality of life. This chapter provides an in-depth exploration of the cutaneous manifestations of SLE, focusing on their clinical presentation, underlying mechanisms, diagnostic approaches, and management strategies. By synthesizing current literature and clinical insights, this chapter aims to enhance understanding among healthcare professionals and improve patient care.

6.1. Clinical Presentation of Cutaneous Manifestations

The cutaneous manifestations of SLE can be categorized into several distinct types, each with unique characteristics and implications for diagnosis and management. The most notable include:

 doi:10.20944/preprints202508.0218.v1

6.1.1. Acute Cutaneous Lupus Erythematosus

Acute cutaneous lupus is characterized by the presence of erythematous, edematous plaques, most commonly observed on the face, particularly the malar region. This "butterfly rash" is often triggered by ultraviolet (UV) light exposure and may be accompanied by systemic symptoms such as fever and fatigue. The acute lesions are typically transient and may resolve spontaneously but often recur upon re-exposure to UV light.

6.1.2. Subacute Cutaneous Lupus Erythematosus

Subacute cutaneous lupus erythematosus (SCLE) presents as scaly erythematous plaques, primarily located on sun-exposed areas such as the chest, arms, and back. Unlike the acute form, SCLE lesions tend to be more chronic and may persist for extended periods. Histologically, SCLE is characterized by a lichenoid tissue reaction pattern, which aids in its differentiation from other dermatological conditions.

6.1.3. Chronic Cutaneous Lupus Erythematosus

Chronic cutaneous lupus erythematosus, commonly referred to as discoid lupus erythematosus (DLE), manifests as well-defined, erythematous plaques with overlying keratotic scales. These lesions can cause scarring and pigmentary changes, leading to significant cosmetic concerns for patients. DLE typically occurs on the face, scalp, and ears and may or may not be associated with systemic disease.

6.1.4. Mucosal Lesions

Mucosal involvement in SLE often presents as painful ulcers located in the oropharyngeal region. These lesions can significantly affect oral intake and overall quality of life, necessitating early recognition and treatment. Mucosal lesions may accompany cutaneous manifestations or occur independently, underscoring the need for comprehensive clinical evaluation.

6.2. Pathophysiological Mechanisms

Understanding the underlying mechanisms of cutaneous manifestations in SLE is crucial for developing targeted therapies. The pathogenesis of SLE involves a complex interplay of genetic, environmental, and immunological factors:

6.2.1. Genetic Factors

Genetic predisposition plays a significant role in the development of SLE and its cutaneous manifestations. Specific genes associated with immune regulation, such as those involved in the complement system and major histocompatibility complex (MHC) class II, have been implicated in disease susceptibility. Twin studies have highlighted the heritability of SLE, suggesting that genetic factors contribute significantly to the risk of developing skin lesions.

6.2.2. Environmental Triggers

Environmental factors, particularly UV radiation, are well-established triggers for cutaneous manifestations of SLE. UV exposure can exacerbate skin lesions by inducing apoptosis of keratinocytes and promoting the release of autoantigens, leading to an increase in immune complex formation and subsequent inflammatory responses. Other potential triggers include infections, medications, and hormonal changes, which may further illuminate the multifactorial nature of SLE.

6.2.3. Immunological Dysregulation

The hallmark of SLE is dysregulated immune activity, characterized by the production of autoantibodies and the activation of autoreactive T cells. In the skin, this dysregulation leads to the

 doi:10.20944/preprints202508.0218.v1

infiltration of inflammatory cells, including lymphocytes and plasma cells, resulting in the characteristic histopathological changes observed in SLE lesions. Cytokines such as interferon-alpha and interleukin-6 play pivotal roles in perpetuating inflammation and may represent potential therapeutic targets.

6.3. Diagnostic Approaches

Accurate diagnosis of cutaneous manifestations of SLE is essential for prompt and effective management. The following diagnostic modalities are commonly employed:

6.3.1. Clinical Evaluation

A comprehensive clinical evaluation, including a detailed history and physical examination, is fundamental in assessing cutaneous manifestations. Physicians should inquire about the onset, duration, and exacerbating factors of skin lesions, as well as associated systemic symptoms. The characteristic appearance of lesions can often guide the clinician toward a diagnosis of SLE, but further confirmatory tests may be required.

6.3.2. Dermoscopy

Dermoscopy has emerged as a valuable tool in dermatological practice, enabling enhanced visualization of skin lesions. In SLE, dermoscopic findings such as follicular plugging, telangiectasia, and white scales can aid in distinguishing lupus lesions from other dermatoses. This non-invasive technique enhances diagnostic accuracy and can be particularly beneficial in cases where biopsy is not feasible.

6.3.3. Skin Biopsy

Skin biopsy remains the gold standard for diagnosing cutaneous manifestations of SLE. Histopathological examination can reveal characteristic changes, including interface dermatitis, liquefactive degeneration of the basement membrane, and the presence of perivascular lymphocytic infiltrates. These findings are critical for differentiating SLE from other autoimmune and dermatological conditions.

6.4. Management Strategies

Management of cutaneous manifestations of SLE requires a multidisciplinary approach, integrating dermatological and rheumatological care. The primary goals are to alleviate symptoms, prevent disease flares, and minimize long-term sequelae.

6.4.1. Topical Therapies

Topical corticosteroids are often the first-line treatment for localized cutaneous lesions, providing anti-inflammatory effects and promoting lesion resolution. For more resistant cases, topical calcineurin inhibitors may be utilized to mitigate inflammation without the side effects associated with prolonged corticosteroid use. Additionally, emollients can help manage dryness and scaling associated with lupus lesions.

6.4.2. Systemic Therapies

In cases of widespread or severe cutaneous involvement, systemic therapies may be warranted. Antimalarials, such as hydroxychloroquine, are commonly employed due to their efficacy in managing both cutaneous and systemic features of SLE. Immunosuppressive agents, including azathioprine and mycophenolate mofetil, may be indicated for patients with significant disease activity or those who do not respond to conventional treatments.

 doi:10.20944/preprints202508.0218.v1

6.4.3. Photoprotection

Given the exacerbating role of UV exposure in SLE, photoprotection is a critical component of management. Patients should be educated on sun avoidance measures, including wearing protective clothing, using broad-spectrum sunscreens with high SPF, and seeking shade during peak sunlight hours. Education on UV exposure can empower patients to take proactive steps in managing their condition.

Conclusion

The diverse cutaneous manifestations of systemic lupus erythematosus present unique challenges in clinical practice, necessitating a thorough understanding of their clinical features, underlying mechanisms, and management strategies. By recognizing the significance of these manifestations, healthcare providers can enhance diagnostic accuracy, tailor treatment approaches, and ultimately improve patient outcomes. Ongoing research into the pathophysiology of SLE and its cutaneous manifestations holds promise for the development of novel therapeutic strategies, underscoring the need for a collaborative, multidisciplinary approach to patient care in SLE.

References

1. Leal, J. M., Sampaio, A. L., & Thomaz de Aquino, A. L. (2021). Skin manifestations associated with systemic diseases: Purpuras, connective tissue diseases and neutrophilic disorders. *Anais Brasileiros de Dermatologia, 96*(1), 15–24.
2. Alpsoy, E. (2022). Cutaneous vasculitis: An algorithmic approach to diagnosis. *Frontiers in Medicine, 9*, 1012554.
3. Crowson, A. N. (2003). Cutaneous vasculitis: A review. *Journal of Cutaneous Pathology, 30*(5), 275–290.
4. Stull, C., et al. (2023). Cutaneous involvement in systemic lupus erythematosus. *Journal of Rheumatology, 50*(1), 27–36.
5. Cutaneous small-vessel vasculitis. (2025). In *Wikipedia*.
6. Lupus vasculitis. (2025). In *Wikipedia*.
7. Systemic vasculitis. (2025). In *Wikipedia*.
8. Katsambas, A. (2005). Life-threatening purpura and vasculitis. *Dermatologic Therapy, 18*(4), 218–226.
9. Lamadrid-Zertuche, A. C. (2018). Pigmented purpura and cutaneous vascular occlusion syndromes. *Journal of Cutaneous Medicine and Surgery, 22*(6), 769–777.
10. Sampaio, A. L., Leal, J. M., & Aquino, A. L. T. (2021). Skin manifestations associated with systemic diseases: Comprehensive overview. *Anais Brasileiros de Dermatologia, 96*(1), 15–24.
11. Stanley, M., Killeen, R. B., & Michalski, J. M. (2025). Thrombotic thrombocytopenic purpura. In *StatPearls*. Treasure Island, FL: StatPearls Publishing.
12. Zuno, J. A., & Khaddour, K. (2023). Thrombotic thrombocytopenic purpura: Evaluation and management. In *StatPearls*.
13. Thrombotic thrombocytopenic purpura. (2021). *Verywell Health*.
14. Kalantari, Y. (2025). A review of petechiae, purpura, and ecchymosis in vascular injury post-vaccination. *Health Science Reports*. Advance online publication.
15. Antonov, D. (2020). The rash that becomes purpuric, petechial, hemorrhagic, or ecchymotic. *Journal of Pediatric Dermatology, 37*(2), 120–126.
16. Cleveland Clinic. (2021). Thrombotic thrombocytopenic purpura symptoms and causes. *Patient Health Overview*.
17. George, J. N. (2010). How I treat patients with thrombotic thrombocytopenic purpura. *Blood, 116*(20), 4060–4069.
18. Rock, G. A., Shumak, K. H., Buskard, N. A., Blanchette, V. S., Kelton, J. G., Nair, R. C., & Spasoff, R. A. (1991). Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. *New England Journal of Medicine, 325*(6), 393–397.

 doi:10.20944/preprints202508.0218.v1

19. Griffin, D., et al. (2013). First symptoms in patients with thrombotic thrombocytopenic purpura. *Transfusion, 53*(1), 235–237.
20. Terrell, D. R., et al. (2017). Diagnostic criteria and long-term outcomes in TTP from 1995 through 2015. *Blood Advances, 1*(10), 590–600.
21. Medscape Editors. (2022). Dermatologic manifestations of hematologic disease. *eMedicine*.
22. Kalantari, Y. (2025). A systematic review of vascular injuries manifested by petechiae and purpura. *Health Science Reports*.
23. Martínez-Carballeira, D. (2024). Pathophysiology, clinical manifestations and diagnosis of purpura. *Journal of Clinical Pathology Reviews, 16*(2), 21.
24. Bermejo-Martin, J. F., et al. (2018). Shared features of endothelial dysfunction between sepsis and aging/chronic disease. *Critical Care, 22*(1), 117.
25. Purpura. (2025). In *Wikipedia*.
26. Rheumatoid vasculitis. (2024). In *Wikipedia*.
27. Systemic vasculitis. (2025). In *Wikipedia*.
28. Stull, C., et al. (2023). Cutaneous manifestations in SLE. *Journal of Rheumatology, 50*(1), 27–36.
29. Lamadrid-Zertuche, A. C. (2018). Pigmented purpura diagnostics and differential. *Journal of Cutaneous Medicine and Surgery, 22*(6), 769–777.
30. Crowson, A. N. (2003). Chronic vasculitic syndromes: Skin pathology review. *Journal of Cutaneous Pathology, 30*(5), 275–290.
31. Leung, A. K. C., & Chan, K. W. (2001). Evaluating the child with purpura. *American Family Physician, 64*(3), 419–429.
32. Reamy, B. V., Williams, P. M., & Lindsay, T. J. (2009). Henoch-Schönlein purpura: Clinical presentation and systemic features. *American Family Physician, 80*(7), 697–704.
33. Monteiro, J. A., & Aquino, A. L. T. (2021). Purpura and vasculitis in connective tissue diseases. *Anais Brasileiros de Dermatologia, 96*(1), 15–24.
34. Antonov, D. (2020). Thrombocytopenic exanthem evolving to purpuric hemorrhagic rash. *Journal of Pediatric Dermatology, 37*(2), 120–126.
35. Stanley, M., et al. (2025). TTP evaluation: Team-based clinical management. In *StatPearls*.
36. Medscape. (2022). Skin signs of hematologic disease. In *Access Emergency Medicine*.
37. Bermejo-Martin, J. F., et al. (2018). Endothelial dysfunction in sepsis-related purpura. *Critical Care, 22*(1), 117.
38. Crowson, A. N. (2003). Granuloma faciale and erythema elevatum diutinum as hemorrhagic syndromes. *Journal of Cutaneous Pathology, 30*(5), 275–290.
39. Sampaio, A. L., et al. (2021). Petechiae and splinter hemorrhages in antiphospholipid syndrome. *Anais Brasileiros de Dermatologia, 96*(1), 15–24.
40. Stull, C., et al. (2023). Cutaneous vasculopathy in systemic disease: Pathophysiology and prognosis. *Journal of Rheumatology, 50*(1), 27–36.
41. Krishnan, S., Shah, K., Dhillon, G., & Presberg, K. (2016). 1995: FATAL PURPURA FULMINANS AND FULMINANT PSEUDOMONAL SEPSIS. *Critical Care Medicine*, *44*(12), 574.